Goldman Sachs reiterated its Buy rating on Geron (NASDAQ:GERN) Corporation (NASDAQ:GERN) with a steady price target of $6.00. The firm's optimism follows the Centers for Medicare & Medicaid Services' (CMS) establishment of a new billing code for Geron's drug Rytelo, starting January 1, 2025. This development is aligned with the company's previous communications regarding the first quarter of 2025.
The newly assigned HCPCS Level II code, J0870, will allow for Rytelo injections of 1mg to be billed, which is expected to enhance the drug's commercial adoption, particularly among physicians in smaller community hospitals and private practices. The ease of reimbursement is seen as a key factor in supporting the drug's uptake.
Goldman Sachs expressed confidence in Rytelo's market potential, citing recent analyses of hematology drug launches, insights from key opinion leaders (KOLs), and third-party data. These sources indicate a strong possibility of Rytelo outperforming near-term revenue expectations.
The initial sales quarters of Rytelo are anticipated to be telling for the drug's sales trajectory. Goldman Sachs has forecasted that Rytelo could reach global peak sales of $1.2 billion. The firm's bullish stance on the stock remains unchanged, encouraged by Geron's commercial execution and the potential for Rytelo in the market.
In other recent news, Geron Corporation's new drug Rytelo, approved for lower-risk myelodysplastic syndromes, has shown promising early adoption trends. Goldman Sachs reaffirmed its Buy rating on the company, noting strong demand trends for Rytelo in its initial launch months and estimating global peak sales reaching $1.2 billion. Similarly, Leerink Partners initiated coverage with an Outperform rating, projecting peak sales of approximately $1.4 billion in the United States.
Geron Corporation appointed Jim Ziegler as Executive Vice President, Chief Commercial Officer. Ziegler's extensive experience in the biopharmaceutical industry is expected to enhance Geron's commercial strategy, particularly for Rytelo.
Geron Corporation is also engaged in a Phase 3 clinical trial for imetelstat in relapsed/refractory myelofibrosis, further solidifying its focus on blood cancer treatments. The company's financial position remains robust, with $430 million in cash and equivalents as of mid-2024, and projected operating expenses for 2024 estimated between $270 million and $280 million.
InvestingPro Insights
Geron Corporation's recent developments, as highlighted in Goldman Sachs' reiterated Buy rating, are further supported by key financial metrics and insights from InvestingPro. The company's market capitalization stands at $2.66 billion, reflecting investor confidence in its potential.
InvestingPro Tips indicate that Geron holds more cash than debt on its balance sheet, which is crucial for a biotech company in the commercialization phase of a new drug like Rytelo. This strong financial position aligns with Goldman Sachs' optimism about Geron's commercial execution capabilities.
Moreover, analysts anticipate sales growth for Geron in the current year, which corroborates Goldman Sachs' positive outlook on Rytelo's market potential. The company's revenue growth of 205.11% over the last twelve months and an impressive 2941.38% quarterly growth in Q2 2024 underscore the significant commercial progress Geron is making.
However, it's worth noting that Geron is currently trading at a high revenue valuation multiple, which may reflect the market's high expectations for Rytelo's success. This valuation should be considered in light of Goldman Sachs' peak sales forecast of $1.2 billion for the drug.
For investors seeking a more comprehensive analysis, InvestingPro offers 11 additional tips for Geron Corporation, providing a deeper understanding of the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.